Garderet L, Snell V, Przepiorka D, Schenk T, Lu J G, Marini F, Gluckman E, Andreeff M, Champlin R E
Department of Molecular Hematology and Therapy, University of Texas M.D. Anderson Cancer Center, Houston 77030-4095, USA.
Transplantation. 1999 Jan 15;67(1):124-30. doi: 10.1097/00007890-199901150-00021.
T cells present in an allogeneic bone marrow transplant may produce graft-versus-host disease but also contribute to immune reconstitution and enhance engraftment. Our aim was to separate alloreactive from nonalloreactive T lymphocytes, by performing a mixed lymphocyte culture (MLC) stimulation of donor cells, followed by selective depletion of activated cells expressing the high-affinity interleukin 2 receptor. We then characterized the resulting depleted cell fraction.
Donor peripheral blood mononuclear cells were cocultured with irradiated peripheral blood mononuclear cells from HLA-nonidentical recipient stimulators in an MLC. After 3 days, CD25+ lymphocytes (alloreactive cells expressing the alpha chain of the interleukin 2 receptor) were removed by immunomagnetic separation. The depleted donor fraction and untreated cells were then rechallenged in a secondary MLC with the original irradiated stimulator cells or a third party to assess relative alloreactivity.
Inhibition of the secondary MLC and of host-specific cytotoxic activities was observed as well as a disappearance of interleukin 2 receptor-positive cells. Alloreactivity against unrelated third-party cells was preserved. Limiting dilution analysis of residual alloantigen-reactive T lymphocytes demonstrated a 1.3 log reduction of antihost reactivity. The depletion largely removed host-specific alloreactive CD4+ cells.
This method reduces alloreactivity while retaining reactivity against third-party targets. This approach may allow therapeutic infusion of T cells after HLA-nonidentical allografts with a reduced capacity to produce graft-versus-host disease.
同种异体骨髓移植中存在的T细胞可能会引发移植物抗宿主病,但也有助于免疫重建并增强植入。我们的目的是通过对供体细胞进行混合淋巴细胞培养(MLC)刺激,然后选择性去除表达高亲和力白细胞介素2受体的活化细胞,将同种异体反应性T淋巴细胞与非同种异体反应性T淋巴细胞分离。然后我们对所得的去除细胞部分进行了表征。
在MLC中将供体外周血单个核细胞与来自HLA不匹配受体刺激物的辐照外周血单个核细胞共培养。3天后,通过免疫磁珠分离去除CD25 +淋巴细胞(表达白细胞介素2受体α链的同种异体反应性细胞)。然后将去除细胞后的供体部分和未处理的细胞在二次MLC中用原始辐照刺激细胞或第三方再次刺激,以评估相对同种异体反应性。
观察到二次MLC和宿主特异性细胞毒性活性受到抑制,以及白细胞介素2受体阳性细胞消失。对无关第三方细胞的同种异体反应性得以保留。对残留的同种异体抗原反应性T淋巴细胞进行极限稀释分析表明,抗宿主反应性降低了1.3个对数。这种去除方法在很大程度上去除了宿主特异性同种异体反应性CD4 +细胞。
该方法降低了同种异体反应性,同时保留了对第三方靶标的反应性。这种方法可能允许在HLA不匹配的同种异体移植后治疗性输注T细胞,同时降低产生移植物抗宿主病的能力。